您当前的位置：

Prinoxodan

(Synonyms: RGW2938)

目录号: PL09643 纯度: ≥99%

Prinoxodan (RGW2938) 是一种磷酸二酯酶抑制剂。

CAS No. :111786-07-3

商品编号	规格	价格	会员价
PL09643-1mg	1mg	¥4018.00	请登录
PL09643-5mg	5mg	¥9965.00	请登录
PL09643-10mg	10mg	¥15912.00	请登录
PL09643-50mg	50mg	询价	询价
PL09643-100mg	100mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	Prinoxodan
中文别名	普啉索旦
英文名称	Prinoxodan
英文别名	2(1H)-Quinazolinone,3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-;3-methyl-6-(6-oxo-4,5-dihydro-1H-pyridazin-3-yl)-1,4-dihydroquinazolin-2-one;Prinoxodan;2(1H)-Quinazolinone,3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl);3,4-Dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1H)-quinazolinone;Prinoxodano;Prinoxodano [INN-Spanish];Prinoxodanum;Prinoxodanum [INN-Latin];RGW 2938
Cas No.	111786-07-3
分子式	C₁₃H₁₄N₄O₂
分子量	258.28
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	Prinoxodan (RGW2938) 是一种磷酸二酯酶抑制剂。

产品详情	Prinoxodan (RGW2938) 是一种磷酸二酯酶抑制剂。
生物活性	Prinoxodan (RGW2938) is a phosphodiesterase inhibitor.
性状	Solid
IC50 & Target[1][2]	Phosphodiesterase
体外研究(In Vitro)	Prinoxodan (RG W-2938) is an orally effective positive inotropic/vasodilator agent. Prinoxodan is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vitro in isolated guinea pig hearts; in the latter, Prinoxodan 5 nmol-5 μmol increases contractility in a dose-related fashion. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and de
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Artigou JY, et al. [Evaluation of a new cardiotonic agent on human isolated atrium]. Ann Cardiol Angeiol (Paris). 1993 Feb;42(2):79-82. [2]. Barrett JA, et al. Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity. J Cardiovasc Pharmacol. 1990 Oct;16(4):537-45.

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Artigou JY, et al. [Evaluation of a new cardiotonic agent on human isolated atrium]. Ann Cardiol Angeiol (Paris). 1993 Feb;42(2):79-82.
[2]. Barrett JA, et al. Pharmacology of RG W-2938: a cardiotonic agent with vasodilator activity. J Cardiovasc Pharmacol. 1990 Oct;16(4):537-45.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

Prinoxodan

相关产品

The molarity calculator equation

The dilution calculator equation